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Translational Relevance 56 
Poly(ADP-ribose) polymerase-1 (PARP-1), PARP-2, and PARP-3 enzymes are key 57 
mediators of DNA repair in response to single-strand breaks. Inhibition of these enzymes 58 
results in accumulation of double-strand DNA breaks that are repaired through BRCA1- and 59 
BRCA2-mediated homologous recombination (HR). Defects in HR repair (eg, BRCA1 and 60 
BRCA2 mutations) can sensitize tumors to PARP inhibition through synthetic lethality. This 61 
phase I–II study was the first to fully evaluate single-agent oral rucaparib, a PARP inhibitor, 62 
in heavily pretreated patients with advanced solid tumors. In Part 1, pharmacokinetics were 63 
dose proportional, safety was manageable, and rucaparib 600 mg twice daily was the 64 
recommended phase II dose. In Part 2A, rucaparib 600 mg twice-daily treatment had robust 65 
antitumor activity in patients with platinum-sensitive ovarian cancer and a germline BRCA1/2 66 
mutation. These results support further clinical and translational investigation of rucaparib in 67 
tumors with HR repair deficiency, potentially extending applicability beyond BRCA-mutated 68 
cancers.69 
Abstract 70 
Purpose: Rucaparib is a potent, oral, small-molecule poly(ADP-ribose) polymerase inhibitor. 71 
This phase I–II study was the first to evaluate single-agent oral rucaparib at multiple doses.  72 
Experimental Design: Part 1 (phase I) sought to determine the maximum tolerated dose 73 
(MTD), recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib 74 
administered in 21-day continuous cycles in patients with advanced solid tumors. Part 2A 75 
(phase II) enrolled patients with platinum-sensitive, high-grade ovarian carcinoma (HGOC) 76 
associated with a germline BRCA1/2 mutation who received two to four prior regimens and 77 
had a progression-free interval of 6 months or more following their most recent platinum 78 
therapy. The primary endpoint was investigator-assessed objective response rate (ORR) by 79 
Response Evaluation Criteria in Solid Tumors version 1.1.  80 
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Results: In Part 1, 56 patients received oral rucaparib (40 to 500 mg once daily and 240 to 81 
840 mg twice daily [BID]). No MTD was identified per protocol-defined criteria; 600 mg BID 82 
was selected as the RP2D based on manageable toxicity and clinical activity. 83 
Pharmacokinetics were approximately dose-proportional across all dose levels. In Part 2A, 84 
42 patients with germline BRCA1/2-mutated HGOC received rucaparib 600 mg BID. 85 
Investigator-assessed ORR was 59.5%. The most common treatment-emergent adverse 86 
events (all grades) were asthenia/fatigue (85.7%; 36/42), nausea (83.3%; 35/42), anemia 87 
(71.4%; 30/42), alanine transaminase and/or aspartate transaminase elevations (57.1%; 88 
24/42), and vomiting (54.8%; 23/42). Among 98 patients, five (5.1%) discontinued because 89 
of an adverse event (excluding disease progression).  90 
Conclusions: Rucaparib was tolerable and had activity in patients with platinum-sensitive 91 
germline BRCA1/2-mutated HGOC.  92 
Trial registration ID: NCT01482715 93 
 94 
Introduction 95 
Poly(ADP-ribose) polymerase (PARP) enzymes make up a 17-member superfamily of 96 
nuclear enzymes; PARP-1, -2, and -3 are activated by and promote the repair of DNA 97 
damage (1). PARP-1 and -2 are the most abundant enzymes and have a major role in the 98 
repair of DNA single-strand breaks through the base excision repair/single-strand break 99 
repair pathway (1). PARP inhibition results in accumulation of unrepaired single-strand 100 
breaks, which result in collapsed replication forks and an accumulation of DNA double-101 
strand breaks (2, 3). These double-strand breaks are repaired by the homologous 102 
recombination (HR) repair pathway, in which BRCA1 and BRCA2 are key proteins (4-6). It is 103 
widely accepted that tumors with a BRCA1/2 mutation or other HR deficiency (HRD) are 104 
selectively sensitive to PARP inhibition by a mechanism of synthetic lethality (7-9). Several 105 
recent reports have proposed additional models by which PARP inhibition may result in 106 
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synthetic lethality (10, 11). For example, PARP inhibition may affect the role these enzymes 107 
play in the alternative nonhomologous end-joining DNA repair pathway, which is upregulated 108 
in HR-deficient cells (12, 13). Additionally, PARP inhibitors have been shown to trap PARP-1 109 
and -2 at the site of the DNA break (14). These trapped PARP-DNA complexes may directly 110 
damage the cell by obstructing replication forks, requiring HR repair for resolution (10, 14). 111 
Several PARP inhibitors are currently in development for the treatment of patients with 112 
tumors harboring HRD, including those with a BRCA1/2 mutation (15-26). Single-agent 113 
olaparib is approved in the United States for the treatment of patients with advanced 114 
germline BRCA1/2-mutated ovarian cancer who have received three or more lines of 115 
chemotherapy (27, 28). Rucaparib (CO-338; formerly known as AG-014447 and PF-116 
01367338) is a potent small molecule inhibitor of PARP-1, -2, and -3 (29, 30), and was 117 
approved in the United States in December 2016 for the treatment of patients with advanced 118 
ovarian cancer associated with deleterious germline or somatic BRCA mutations who have 119 
received two or more chemotherapies (31). Consistent with the concept of synthetic lethality, 120 
rucaparib is preferentially cytotoxic to cells with a BRCA1 or BRCA2 mutation or 121 
epigenetically silenced BRCA1 (7, 32).  122 
An open-label, phase II study investigated intermittent dosing of intravenous rucaparib (5 123 
days of a 21-day cycle), as well as intermittent and continuous dosing of oral rucaparib (7, 124 
14, or 21 days of a 21-day cycle) in small cohorts of patients with advanced ovarian or 125 
breast cancer associated with a germline BRCA1/2 mutation (33). This study provided 126 
evidence that continuous dosing of oral rucaparib led to a higher rate of response than 127 
intermittent intravenous dosing (response rate, 18% vs. 2%). The intravenous formulation 128 
was discontinued. However, the maximum oral dose of rucaparib 600 mg BID for 21 129 
continuous days was only evaluated in one patient, and the study did not establish a 130 
recommended phase II dose (RP2D) for the oral formulation, which was a secondary 131 
endpoint.   132 
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The phase I–II study reported here was the first to fully evaluate single-agent oral rucaparib 133 
administered for multiple cycles in patients with an advanced solid tumor, including a cohort 134 
of patients with BRCA1/2-mutated ovarian cancer who had received multiple prior 135 
treatments. The objectives of this study included characterization of the safety and 136 
pharmacokinetic (PK) profiles, assessment of preliminary clinical activity, and establishment 137 
of the RP2D of rucaparib. Here we present results from Study 10 Part 1 (phase I dose 138 
escalation), as well as Part 2A (phase II expansion) that evaluated the RP2D of rucaparib as 139 
single-agent treatment in patients with platinum-sensitive, high-grade ovarian cancer 140 
(HGOC) associated with a germline BRCA1/2 mutation.  141 
 142 
Materials and Methods 143 
Study design and patients 144 
This is an ongoing, three-part, open-label, phase I–II study of single-agent oral rucaparib 145 
(ClinicalTrials.gov identifier, NCT01482715). It was approved by the institutional review 146 
board at each study site and is being conducted in accordance with the Declaration of 147 
Helsinki and the Good Clinical Practice Guidelines of the International Conference on 148 
Harmonisation. Patients provided written consent before participating in the study. Part 1 149 
(phase I dose escalation) enrolled patients who were at least 18 years of age with an 150 
advanced solid tumor that had progressed on standard treatment. Eligible patients had an 151 
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1 and 152 
adequate hematologic, hepatic, and renal function. Measurable disease and a known 153 
BRCA1/2 mutation were not required. The primary objectives of Part 1 were to characterize 154 
the safety and PK profile of oral rucaparib administered as a continuous daily dose and 155 
establish the maximum tolerated dose (MTD) and RP2D in patients with an advanced solid 156 
tumor. Antitumor activity was evaluated as a secondary objective.  157 
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Part 2A (phase II expansion) evaluated the RP2D of oral rucaparib in patients with platinum-158 
sensitive, relapsed, high-grade serous or endometrioid epithelial ovarian, fallopian tube, or 159 
primary peritoneal cancer associated with a germline BRCA1/2 mutation. Eligible patients 160 
received between two and four prior treatment regimens, had an ECOG PS of 0 to 1, had a 161 
progression-free interval (PFI) of 6 months or longer after their most recent platinum-based 162 
regimen, and had measurable disease (of any size; with or without visceral metastasis) per 163 
Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST). Part 2A utilized a 164 
Simon two-stage design requiring two or more responses in the first 21 patients to continue 165 
to stage 2; total planned enrollment was 41 patients. The primary endpoint was investigator-166 
assessed objective response rate (ORR) per RECIST. Secondary objectives included 167 
evaluation of duration of response and safety. An independent radiology review of ORR for 168 
patients in Part 2A was performed retrospectively. 169 
Study treatment 170 
Using a standard 3 + 3 design for dose escalation (Part 1), patients received oral rucaparib 171 
once daily (QD) or twice daily (BID) in 21-day continuous treatment cycles, starting at 40 mg 172 
QD with escalations to 80, 160, 300, and 500 mg QD, then further escalation to 240, 360, 173 
480, 600, and 840 mg BID. The protocol was amended approximately 10 months after 174 
enrollment began to allow intrapatient dose escalation. Patients in Part 2A received the 175 
RP2D of oral rucaparib established in Part 1. Treatment continued until disease progression 176 
or unacceptable toxicity. A new cycle of treatment could begin if a patient’s absolute 177 
neutrophil count was 1.0 × 109/L or greater, platelet count was 75.0 × 109/L or greater, and 178 
nonhematologic toxicities had returned to baseline or were grade 1 or less. 179 
Definition of dose-limiting toxicity and maximum tolerated dose 180 
In Part 1, dose-limiting toxicities (DLTs) were defined as any of the following events that 181 
occurred during cycle 1 and were assessed by the investigator as related to rucaparib: 182 
absolute neutrophil count less than 0.5 × 109/L lasting for more than 5 days or febrile 183 
neutropenia; platelets less than 25 × 109/L or platelets less than 50 × 109/L with bleeding 184 
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requiring a platelet transfusion; grade 4 anemia; or any nonhematologic adverse event (AE) 185 
grade 3 or greater (except nausea, vomiting, and diarrhea, if well controlled by systemic 186 
medication, and alopecia). Dose escalation continued until 33% or more of patients treated 187 
at a dose level experienced a DLT. The next lower dose was then considered the MTD. 188 
Pharmacokinetics, safety, and efficacy assessments 189 
Pharmacokinetic assessments in Part 1 included single-dose and steady-state (day 15) 190 
profiles in cycle 1 and trough levels in selected cycles. Blood was collected prior to rucaparib 191 
dosing and from 15 minutes to 24 hours after dosing on days 1 and 15. Samples for PK 192 
analysis were collected before and/or after the morning dose for all patients on a BID dosing 193 
schedule. Safety assessments included evaluation of AEs, hematology, clinical chemistry, 194 
vital signs, body weight, concomitant medications and/or procedures, ECOG PS, 195 
electrocardiograms, and rucaparib dose modifications. Adverse events were classified 196 
according to the National Cancer Institute Common Terminology Criteria for Adverse Events 197 
version 4 (34).  198 
Tumor assessments consisted of clinical examination and computed tomography scans of 199 
the chest, abdomen, and pelvis (with appropriate slice thickness per RECIST) (35). Other 200 
assessments (eg, magnetic resonance imaging) were performed only if clinically required. 201 
Tumor assessments were performed at screening, prior to cycles 3, 5, and 7, and every 202 
three cycles of treatment thereafter from cycle 10. Tumor responses (per RECIST) were 203 
assessed in all patients; however, for those without measurable disease at baseline 204 
(permitted in Part 1), only a best response of stable or progressive disease could be 205 
achieved. Response in patients with ovarian cancer was also assessed using Gynecologic 206 
Cancer Intergroup (GCIG) cancer antigen 125 (CA-125) criteria (36). Confirmatory scans 207 
were required 4 to 6 weeks after an initial complete response (CR) or partial response (PR) 208 
was noted. 209 
Dose reductions 210 
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Up to three dose reduction steps were permitted to manage treatment-related toxicity. In the 211 
event of grade 3 or 4 toxicity, treatment was held until resolution to grade 2 or less before re-212 
administration of rucaparib. If dosing was interrupted for more than 14 consecutive days 213 
because of toxicity, treatment was discontinued unless the patient was deriving clinical 214 
benefit and the sponsor approved continuation of treatment. In Part 1, rucaparib was 215 
reduced to the next lower dose level. In Part 2A, rucaparib dose was reduced by increments 216 
of 120 mg. 217 
Statistical analysis 218 
For Part 1, it was estimated that six to 12 dose-escalation cohorts, with a minimum of three 219 
patients each, would be needed to evaluate the RP2D of oral rucaparib. In Part 2A, it was 220 
estimated that at least 41 patients evaluable for response would be needed to evaluate the 221 
efficacy of rucaparib.  222 
The single-dose and steady-state rucaparib PK data following oral administration were 223 
analyzed using noncompartmental methods. The PK parameters included area under the 224 
concentration time curve (AUC) from time 0 to last measurable concentration, maximum 225 
concentration (Cmax), time to Cmax (Tmax), half-life (T1/2), apparent steady-state clearance 226 
(CLss/F), and accumulation ratio. Time to reach steady state was estimated based on the 227 
plasma trough concentration-time profile. Dose proportionality was assessed for QD and BID 228 
dosing using log-transformed PK parameters and dose by linear regression. The effect of 229 
food on single-dose rucaparib exposure, as measured by Cmax and AUC time zero to 24 230 
hours (AUC0-24), was assessed at the 40 and 300 mg QD dose levels. 231 
Safety analyses were performed by study part and by dose level in all patients who received 232 
at least one dose of rucaparib. The ORR was summarized for all patients enrolled in Part 2A 233 
who received at least one dose of rucaparib, and presented as percentages with 95% 234 
confidence intervals (CIs) using Clopper-Pearson methodology. Duration of confirmed 235 
response (CR or PR) was measured from the date of first response until the date that 236 
progressive disease was objectively documented, or censored at the last tumor evaluation. 237 
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Kaplan-Meier methodology was used to analyze duration of response and presented with 238 
the median and 95% CI.   239 
 240 
RESULTS 241 
Part 1 (phase I dose escalation) 242 
Patients and treatments. Between December 2011 and October 2013, 56 patients were 243 
enrolled into Part 1 of the study. Results from Part 1 are based on a visit cutoff date of 244 
November 30, 2015.  245 
Baseline characteristics are presented in Table 1. Most patients had either breast (48.2%; 246 
27/56) or ovarian (35.7%; 20/56) cancer. The majority of patients (64.3%; 36/56) had a 247 
germline BRCA1 or BRCA2 mutation identified by local testing; for seven of 56 patients 248 
(12.5%), germline status was not confirmed as local BRCA testing was conducted using 249 
DNA extracted from tissues other than blood or buccal samples (eg, tumor tissue only). For 250 
20 of 56 patients (35.7%), a BRCA mutation was not detected or no test was performed. 251 
Twenty-six patients received rucaparib QD, at dose levels of 40 mg (n = 6), 80 mg (n = 3), 252 
160 mg (n = 4), 300 mg (n = 9), and 500 mg QD (n = 4); 30 patients received rucaparib BID, 253 
at dose levels of 240 mg (n = 3), 360 mg (n = 8), 480 mg (n = 9), 600 mg (n = 7), and 840 254 
mg BID (n = 3). Median treatment exposure across all dose levels was 3.2 months (range, 255 
0.0–37.9); 20 of 56 patients (35.7%) received treatment for 6 months or more. One of eight 256 
patients treated with rucaparib 360 mg BID experienced a DLT of grade 3 nausea not well 257 
controlled by systemic medication; no DLTs were observed at any other dose level. No MTD 258 
was identified per the protocol-specified criteria.  259 
Safety. Across dose levels, treatment-emergent AEs were mostly grade 1 or 2 in severity.  260 
No grade 4 events were reported (Table 2). The most common (≥20% of patients) treatment-261 
emergent AEs were asthenia/fatigue, gastrointestinal disorders (nausea, vomiting, and 262 
diarrhea), myelosuppression (anemia, thrombocytopenia, and neutropenia), decreased 263 
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appetite, and elevated alanine transaminase (ALT) and/or aspartate transaminase (AST) 264 
levels. Treatment-emergent AEs of elevations in blood creatinine and ALT/AST levels were 265 
reported in 8.9% (5/56) and 25.0% (14/56) of patients and were mostly grade 1 or 2. Anemia 266 
was the most common grade 3 treatment-emergent AE, reported in five of 56 patients (8.9%) 267 
across all doses, with the highest incidence reported with the rucaparib 600 mg BID dose 268 
(28.6%; 2/7). Across all cohorts, 11 of 56 patients (19.6%) had a dose reduction because of 269 
a treatment-emergent AE. At the visit cutoff date (November 30, 2015), two of 56 patients 270 
(3.6%) continued to receive treatment, 50 of 56 patients (89.3%) had discontinued because 271 
of disease progression (71.4%) or clinical deterioration (17.9%), and one patient each (1.8%) 272 
discontinued for the following reasons: vaginal fistula (considered related to disease 273 
progression), CA-125 increase, physician’s decision, or eligibility violation (QTc higher than 274 
the allowed maximum of 450 ms). No treatment-related deaths were reported; three deaths 275 
resulting from disease progression were reported during the study. 276 
Efficacy. In this portion of the study, objective responses or prolonged stable disease (SD) 277 
occurred in patients with a germline BRCA mutation. There were two patients who achieved 278 
a confirmed CR in Part 1 (Table 3). One patient with platinum-sensitive ovarian cancer and a 279 
germline BRCA1 mutation receiving rucaparib 300 mg QD had a PR at 6 weeks (first on-280 
study assessment) and eventually achieved a CR at 54 weeks. At the visit cutoff date, the 281 
patient had been on study for 165 weeks, with a confirmed CR for 111 weeks. A patient with 282 
breast cancer and a germline BRCA1 mutation receiving rucaparib 360 mg BID had a PR at 283 
6 weeks (first on-study assessment) and achieved a CR at 18 weeks, which lasted for 60 284 
weeks. 285 
A confirmed PR was achieved in six patients (Table 3). One patient with breast cancer and a 286 
germline BRCA1 mutation receiving rucaparib 300 mg QD had a PR for 15 weeks. One 287 
patient with pancreatic cancer and a germline BRCA2 mutation receiving rucaparib 360 mg 288 
BID had a PR for 28 weeks. In the rucaparib 480 mg BID cohort, one patient with breast 289 
cancer and a germline BRCA2 mutation, one patient with platinum-resistant ovarian cancer 290 
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and a germline BRCA2 mutation, and one patient with breast cancer and a tumor BRCA1 291 
mutation achieved a PR of 116, 37, and 21 weeks’ duration, respectively. One patient with 292 
platinum-resistant ovarian cancer and a tumor BRCA1 mutation who received rucaparib 600 293 
mg BID had a PR for 13 weeks. Twenty-two patients (15 with ovarian, six with breast, and 294 
one with colon cancer) had a best response of SD; 14 patients had durable SD for more than 295 
24 weeks. Of thirteen patients with ovarian cancer associated with a BRCA mutation who 296 
received rucaparib BID (360 to 840 mg), two (15.4%; 95% CI, 1.9–45.4) achieved a 297 
confirmed PR, 10 (76.9%) had a best response of SD, and one (7.7%) was not evaluable. 298 
The best response in target lesions for all phase I patients with measurable disease is 299 
presented in Fig. 1A.   300 
Pharmacokinetics. Fifty-six patients entered the dose-escalation portion of the study and 301 
received oral rucaparib with or without food at doses ranging from 40 to 500 mg QD and 240 302 
to 840 mg BID (480 to 1680 mg/day). Pharmacokinetic parameters are summarized in Table 303 
4. The mean plasma rucaparib concentration-time profiles by dose level on cycle 1 days 1 304 
and 15 following QD and BID dosing are presented in Supplementary Fig. S1 and Fig. S2, 305 
and the relationship between dose level and exposure is presented in Supplementary Fig. 306 
S3. Plasma exposure of rucaparib was approximately dose proportional. The median values 307 
of Tmax ranged from 1.5 to 6 hours across all doses, suggesting relatively fast absorption. 308 
The estimated T1/2 for QD dosing was approximately 17 hours. Steady state appeared to be 309 
achieved by day 8 with QD or BID dosing based on the predose plasma concentration of 310 
rucaparib. The estimated mean values of CLSS/F ranged from 26.7 to 47.5 L/h for QD dosing 311 
and from 26.2 to 58.6 L/h for BID dosing. The accumulation ratio of rucaparib plasma 312 
exposure at steady state ranged from 1.06 to 1.8 for Cmax and 1.6 to 2.3 for AUC0-24 with QD 313 
dosing, and from 2.6 to 4.9 for Cmax and 1.47 to 5.44 for AUC0-12 with BID dosing. The 314 
accumulation on a BID schedule was approximately twice that of the QD schedule. The time 315 
to steady state and the observed accumulation ratios are consistent with the T1/2 values, 316 
suggesting lack of time-dependent PK. The effect of a high-fat meal on rucaparib PK was 317 
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evaluated in three patients at 40 mg QD and six patients at 300 mg QD. A high-fat meal did 318 
not cause clinically meaningful changes of rucaparib PK at these dose levels 319 
(Supplementary Table S1).  320 
Recommended phase II dose. Based on protocol-specified criteria, no MTD was identified 321 
for dose levels of 40 mg QD up to 840 mg BID in Part 1. The 600 mg BID dose was selected 322 
as the RP2D upon consideration of the manageable safety and antitumor activity of 323 
rucaparib, as well as the PK profile observed in patients in Part 1. No patients in the 600 mg 324 
BID cohort discontinued because of an AE; however, myelosuppression requiring dose 325 
modification was observed in some patients after several cycles of treatment. Furthermore, 326 
antitumor activity was observed in patients in this cohort. 327 
Part 2A (phase II expansion) 328 
Patients and treatments. Part 2A of the study evaluated oral rucaparib in patients with 329 
platinum-sensitive, high-grade serous, endometrioid, mixed histology or clear cell ovarian 330 
cancer associated with a germline BRCA1/2 mutation. The majority of patients had high-331 
grade serous cancer (Table 1). In stage 1, three of the first five patients enrolled achieved a 332 
RECIST response, satisfying the criteria to continue to stage 2. A total of 42 patients were 333 
enrolled into Part 2A; the majority of patients (71.4%; 30/42) had a BRCA1 mutation, and 334 
28.6% (12/42) had a BRCA2 mutation (Table 1). The median number of prior chemotherapy 335 
regimens was two (range, 2–4); 15 of 42 patients (35.7%) had received three or more prior 336 
chemotherapies.  337 
At the visit cutoff date (November 30, 2015), nine of 42 patients (21.4%) remained on 338 
treatment. Twenty-six of 42 patients (61.9%) discontinued because of disease progression 339 
(52.4%) or clinical decline (9.5%), four (9.5%) discontinued because of an AE, two (4.8%) 340 
discontinued because of CA-125 increase, and one (2.4%) discontinued upon investigator 341 
decision. Median treatment exposure was 7.4 months (range, 0.1–20.2).  342 
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Efficacy. Of 42 patients, 25 (59.5%) achieved an investigator-assessed, confirmed RECIST 343 
response and 35 (83.3%) achieved an investigator-assessed, RECIST/GCIG CA-125 344 
response (Table 3). Activity was observed in patients with either a BRCA1 or BRCA2 345 
mutation, those with a PFI of 6 to 12 months or more than 12 months, as well as those who 346 
had received at least three prior chemotherapy regimens. Most patients (60.0%; 15/25) with 347 
a RECIST response achieved a response by the first disease assessment (approximately 6 348 
weeks), and all but two of the responders achieved a response by the second disease 349 
assessment (approximately 12 weeks). The majority of patients (88.1%; 37/42) had a 350 
reduction in target lesion size (Fig. 1B). An example of a patient with visceral disease who 351 
had received two prior platinum-based regimens and achieved a PR to rucaparib at cycle 2 352 
(51% decrease in sum of target lesions) is shown in Supplementary Fig. S4. Notably, the 353 
patient with clear cell ovarian cancer and the patient with endometrioid ovarian cancer each 354 
achieved a PR, as did many patients with serous ovarian cancer; thus the presence of a 355 
BRCA mutation appears to play a larger role than histology in determining response to 356 
rucaparib. The median duration of investigator-assessed confirmed response for patients in 357 
Part 2A was 7.8 months (95% CI, 5.6–10.5). Nine of the 25 responders were censored at the 358 
visit cutoff date. Of these nine patients, five were ongoing and four discontinued treatment 359 
for reasons other than disease progression (Fig. 1C). In a retrospective analysis, the 360 
confirmed ORR by independent radiology review was 52.4% (95% CI, 36.4–68.0).   361 
Safety. Treatment-emergent AEs (all grades) were reported in all 42 patients (100.0%) 362 
(Table 2), the most common of which were asthenia/fatigue, nausea, anemia, ALT/AST 363 
elevations, vomiting, constipation, and headache. Treatment-emergent AEs of elevations in 364 
blood creatinine were reported in 33.3% of patients (14/42) and were grade 1 or 2. Grade 3 365 
or 4 treatment-emergent AEs were reported in 32 of 42 patients (76.2%); those reported in 366 
10% or more of patients included asthenia/fatigue (grade 3, 26.2% [11/42]; grade 4, none), 367 
anemia (grade 3, 31.0% [13/42]; grade 4, 7.1% [3/42]), and elevated ALT/AST (grade 3, 368 
14.3% [6/42]; grade 4, none) (Table 2). Four of 42 patients (9.5%) discontinued treatment 369 
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because of an AE, including abdominal cramp, constipation, dizziness, fatigue, 370 
hypercholesterolemia, nausea, shaking, urinary tract infection, and vomiting; 26 of 42 371 
patients (61.9%) discontinued because of disease progression or clinical deterioration. There 372 
were three deaths that resulted from disease progression; no treatment-related deaths were 373 
reported during the study. 374 
Among 42 patients, treatment-emergent AEs led to a dose reduction in 29 patients (69.0%) 375 
and treatment interruption in 27 patients (64.3%). Thirty-eight patients (90.5%) had at least 376 
one dose reduction or treatment delay because of a treatment-emergent AE. Grade 3 or 4 377 
AEs were managed with treatment modification and/or supportive care. In most patients, 378 
myelosuppression was a cumulative effect that manifested after cycle 1 and was 379 
successfully treated with supportive care and/or dose interruption or modification. Transient 380 
elevations in ALT and/or AST, with no other evidence of liver dysfunction, occurred relatively 381 
early after initiation of treatment (middle of cycle 1 or start of cycle 2) and resolved or 382 
stabilized over time, including during continued rucaparib exposure (Fig. 2). 383 
 384 
Discussion 385 
In this phase I–II study, oral rucaparib had a manageable safety profile and favorable PK 386 
properties. During dose escalation, rucaparib was active in patients who had a germline 387 
BRCA1/2 mutation, with responses observed in patients with ovarian (platinum-sensitive and 388 
platinum-resistant), breast, and pancreatic tumors. Part 2A data indicated that administration 389 
of rucaparib 600 mg BID led to robust responses in patients with platinum-sensitive, 390 
relapsed, high-grade, serous, endometrioid, and/or clear cell ovarian cancer associated with 391 
a germline or tumor BRCA1/2 mutation.  392 
This study was the first to fully evaluate daily, single-agent oral rucaparib in patients with an 393 
advanced solid tumor and to provide a comprehensive characterization of its safety and PK 394 
profile. Continuous dosing of oral rucaparib was associated with approximately dose-395 
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proportional rucaparib exposure in the tested dose ranges following QD and BID 396 
administration, with moderate interpatient variability and a T1/2 of approximately 17 hours 397 
independent of dose. In a small cohort of patients, a high-fat meal did not cause clinically 398 
meaningful changes in rucaparib PK, indicating that patients may take rucaparib with or 399 
without food. During the dose escalation phase of the study (Part 1), no MTD was identified 400 
in patients treated with rucaparib doses up to 840 mg BID; however, delayed 401 
myelosuppression requiring dose modification was observed in some patients treated with 402 
rucaparib 600 mg BID. The 600 mg BID dose was selected as the RP2D based on 403 
manageable safety and clinical activity, and was further characterized in the phase II portion.  404 
Oral rucaparib 600 mg BID was tolerable, with a manageable safety profile that was 405 
consistent with its mechanism of action. Toxicities observed with rucaparib, such as 406 
myelosuppression, fatigue, and gastrointestinal disorders, are commonly observed with 407 
other PARP inhibitors (19, 23, 24, 37, 38). Myelosuppression, which generally occurs at a 408 
lower frequency with PARP inhibitors in relation to platinum-based chemotherapy, was 409 
generally observed after several cycles of rucaparib treatment and was successfully 410 
managed with supportive care and treatment modification (dose reduction and/or 411 
interruption). Other common low-grade AEs included fatigue and gastrointestinal side 412 
effects, such as nausea and vomiting. These AEs were successfully managed with 413 
supportive care and/or dose modification, as needed. Elevated serum creatinine was 414 
observed during rucaparib treatment. Elevations in creatinine have also been observed 415 
following the use of the PARP inhibitor olaparib (27). Elevations in creatinine may be 416 
attributed to the inhibition of the active tubular secretion of creatinine into the proximal tubule 417 
and subsequent apical efflux into the urine, as rucaparib has demonstrated potent inhibition 418 
of MATE1 and MATE2-K and moderate inhibition of OCT-2 in vitro. Inhibition of these 419 
transporters has also been demonstrated in vitro with the PARP inhibitor veliparib and other 420 
drugs (39, 40). Some AEs observed with rucaparib treatment, such as elevations in ALT and 421 
AST, have not been previously associated with PARP inhibitors. The mechanism 422 
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responsible for the transaminase elevations has not been identified; however, such 423 
elevations were transient and resolved or stabilized during treatment. Of the 98 patients 424 
treated in Study 10 (Parts 1 and 2 combined), 87 patients discontinued treatment because of 425 
disease progression (62/98; 63.3%), clinical progression (14/98; 14.3%), treatment-emergent 426 
AE (5/98; 5.1%), or other reason (6/98; 6.1%). No treatment-related deaths were reported in 427 
either Part 1 or Part 2A. 428 
The benefits of PARP inhibitors for treatment of germline BRCA1/2-mutated ovarian cancer 429 
are well established, with response rates in the range of 38% to 60% reported in patients 430 
with platinum-sensitive disease (16, 18, 19, 24, 41-43). In the 42 patients with platinum-431 
sensitive, relapsed HGOC associated with a germline BRCA1/2 mutation enrolled in Part 2A 432 
of this study (600 mg BID), the investigator-assessed ORR was 59.5% by RECIST and 433 
83.3% by RECIST/CA-125 criteria. 434 
Part 2B of this study is currently assessing the efficacy of rucaparib in patients with platinum-435 
sensitive, relapsed HGOC associated with a germline or somatic BRCA1/2 mutation who 436 
had received at least three prior chemotherapy regimens. Part 3 is ongoing and currently 437 
assessing the PK (including the effect of food) and safety profile of a higher dose tablet of 438 
rucaparib in patients with a relapsed solid tumor associated with a germline or somatic 439 
BRCA1/2 mutation.  440 
This study provides evidence of the antitumor activity of rucaparib in patients with germline 441 
BRCA1/2-mutated ovarian cancer. Results from this study and the ongoing phase II ARIEL2 442 
study (NCT01891344) supported the accelerated approval of rucaparib (600 mg BID) by the 443 
United States Food and Drug Administration for the treatment of patients with advanced 444 
ovarian cancer associated with deleterious germline or somatic BRCA mutations who have 445 
received two or more chemotherapies. Additional preclinical data indicate that the antitumor 446 
activity of rucaparib extends beyond tumors with a BRCA1/2 mutation to a broader group of 447 
tumors with HRD (32, 44, 45). For this reason, rucaparib is being developed for the 448 
treatment of tumors with HRD, including those with a BRCA1 or BRCA2 mutation 449 
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(ClinicalTrials.gov identifiers: NCT00664781, NCT01074970, NCT01482715, NCT01891344, 450 
NCT01968213, NCT02042378, and NCT02505048). In addition to the ARIEL2 study, which 451 
is investigating rucaparib in the treatment setting, rucaparib is being evaluated in the 452 
maintenance setting in patients with relapsed HGOC in the phase III ARIEL3 study 453 
(NCT01968213). The ARIEL2 and ARIEL3 studies are enrolling patients with or without a 454 
germline or somatic BRCA1/2 mutation in order to investigate the activity of rucaparib in a 455 
wider group of patients with HRD-associated ovarian cancer. The ARIEL clinical 456 
development program is prospectively testing a novel next-generation sequencing HRD 457 
assay and algorithm to predict which patients with ovarian cancer, including those whose 458 
tumors lack a BRCA1 or BRCA2 mutation, who may benefit from rucaparib. Results from 459 
ARIEL2 Part 1 indicate that some patients who have BRCA1/2 wild-type tumors and have a 460 
high percentage of tumor genomic loss of heterozygosity respond to rucaparib treatment 461 
(43). In ARIEL3, this novel HRD assay will be prospectively applied to the primary analysis 462 
of investigator-assessed progression-free survival by RECIST with the aim of validating the 463 
test to identify patients with HRD tumors who will be most likely to benefit from rucaparib.  464 
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Table 1. Baseline patient and disease characteristics 635 
Parameter 
Part 1
Phase I 
(n = 56) 
Part 2A
Phase II 
(n = 42) 
Age, median (range), y 51 (21–71) 57 (42–84) 
Gender, n (%)   
Female 51 (91.1) 42 (100.0) 
Male 5 (8.9) 0 (0) 
ECOG PS, n (%)   
0 29 (51.8) 26 (61.9) 
1 27 (48.2) 16 (38.1) 
Germline BRCA1/2 mutation, n (%)   
Yes 36 (64.3) 42 (100.0) 
No mutation detected 9 (16.1) 0 (0) 
No test performeda 11 (19.6) 0 (0) 
BRCA gene mutation, n (%)   
BRCA1 22 (39.3) 30 (71.4) 
BRCA2 14 (25.0) 12 (28.6) 
Type of cancer, n (%)   
Breast 27 (48.2) 0 (0) 
Ovarian 20 (35.7) 42 (100.0) 
Pancreatic (exocrine) 2 (3.6) 0 (0) 
Otherb 7 (12.5) 0 (0) 
Histological classification, n (%)   
Serous  NA 37 (88.1) 
Mixed NA 3 (7.1) 
Endometrioid NA 1 (2.4) 
Clear cell NA 1 (2.4) 
Platinum status of patients with ovarian   
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cancer, n (%)c 
Refractory 1 (1.8) 0 (0) 
Resistant 11 (19.6) 0 (0) 
Sensitive 8 (14.3) 42 (100.0) 
Progression-free interval from last 
platinum therapy, n (%) 
  
≥6–12 mo NA 32 (76.2) 
>12 mo NA 10 (23.8) 
Previous anticancer therapies, median 
(range) 
4 (1–15) 2 (2–4) 
≥3 previous anticancer therapies, n (%) 41 (73.2) 15 (35.7) 
Previous chemotherapies, median 
(range) 
3 (1–13) 2 (2–4) 
≥3 previous chemotherapies, n (%) 37 (66.1) 15 (35.7) 
Previous platinum-based 
chemotherapies, median (range) 
1 (0–5) 2 (2–4) 
≥3 previous platinum-based 
chemotherapies, n (%) 
9 (16.1) 13 (31.0) 
aPatients did not have local or central BRCA testing performed. 
bOne each of the following: small-cell lung cancer, gastric cancer, colon 
cancer, desmoplastic round cell tumor, mesenchymal chondrosarcoma of the 
skull, astrocytoma, and angiosarcoma. 
cPlatinum status was not applicable for 36 patients (64.3%) in Part 1. 
NA, not applicable. 
 636 
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Table 2. Treatment-emergent adverse events (occurring in ≥20% of patients in Part 1 or Part 2a) by rucaparib dose 637 
Adverse Event 
Part 1 (Phase I Dose Escalation), n (%) Part 2A (Phase II Expansion), n (%)
40–500 
mg QD 
(n = 26)a 
240 mg 
BID 
(n = 3) 
360 mg
BID 
(n = 8) 
480 mg
BID 
(n = 9) 
600 mg
BID 
(n = 7) 
840 mg
BID 
(n = 3) 
All 
doses 
(n = 56) 
600 mg
BID 
(n = 42) 
All 
Grade 
All 
Grade 
All
Grade 
All
Grade 
All
Grade 
All
Grade 
All 
Grade 
Grade
1 
Grade
2 
Grade
3 
Grade
4 All Grade 
Any adverse event 26 (100.0) 3 (100.0) 8 (100.0) 8 (88.9) 7 (100.0) 3 (100.0) 55 (98.2) 0 (0) 7 (16.7) 26 (61.9) 6 (14.3) 42 (100.0) 
Asthenia/fatigue 10 (38.5) 2 (66.7) 5 (62.5) 5 (55.6) 5 (71.4) 1 (33.3) 28 (50.0) 8 (19.0) 17 (40.5) 11 (26.2) 0 (0) 36 (85.7) 
Nausea 12 (46.2) 0 (0) 6 (75.0) 4 (44.4) 4 (57.1) 3 (100.0) 29 (51.8) 17 (40.5) 15 (35.7) 3 (7.1) 0 (0) 35 (83.3) 
Anemiab 5 (19.2) 0 (0) 4 (50.0) 3 (33.3) 4 (57.1) 1 (33.3) 17 (30.4) 7 (16.7) 7 (16.7) 13 (31.0) 3 (7.1) 30 (71.4) 
AST/ALT increased 2 (7.7) 0 (0) 2 (25.0) 3 (33.3) 6 (85.7) 1 (33.3) 14 (25.0) 11 (26.2) 7 (16.7) 6 (14.3) 0 (0) 24 (57.1) 
Vomiting 10 (38.5) 0 (0) 3 (37.5) 5 (55.6) 4 (57.1) 2 (66.7) 24 (42.9) 12 (28.6) 8 (19.0) 3 (7.1) 0 (0) 23 (54.8) 
Constipation 8 (30.8) 0 (0) 2 (25.0) 2 (22.2) 1 (14.3) 0 (0) 13 (23.2) 15 (35.7) 7 (16.7) 0 (0) 0 (0) 22 (52.4) 
Headache 5 (19.2) 0 (0) 2 (25.0) 1 (11.1) 2 (28.6) 1 (33.3) 11 (19.6) 13 (31.0) 5 (11.9) 1 (2.4) 0 (0) 19 (45.2) 
Abdominal pain 7 (26.9) 0 (0) 2 (25.0) 3 (33.3) 1 (14.3) 1 (33.3) 14 (25.0) 8 (19.0) 7 (16.7) 3 (7.1) 0 (0) 18 (42.9) 
Dysgeusia 1 (3.8) 1 (33.3) 2 (25.0) 1 (11.1) 1 (14.3) 2 (66.7) 8 (14.3) 11 (26.2) 6 (14.3) 0 (0) 0 (0) 17 (40.5) 
Diarrhea 4 (15.4) 1 (33.3) 1 (12.5) 2 (22.2) 2 (28.6) 3 (100.0) 13 (23.2) 8 (19.0) 8 (19.0) 0 (0) 0 (0) 16 (38.1) 
Thrombocytopeniac 0 (0) 0 (0) 1 (12.5) 2 (22.2) 5 (71.4) 0 (0) 8 (14.3) 8 (19.0) 6 (14.3) 1 (2.4) 0 (0) 15 (35.7) 
Blood creatinine 
increased 2 (7.7) 1 (33.3) 0 (0) 1 (11.1) 1 (14.3) 0 (0) 5 (8.9) 9 (21.4) 5 (11.9) 0 (0) 0 (0) 14 (33.3) 
Neutropeniad 3 (11.5) 0 (0) 1 (12.5) 3 (33.3) 3 (42.9) 0 (0) 10 (17.9) 4 (9.5) 2 (4.8) 4 (9.5) 3 (7.1) 13 (31.0) 
Decreased appetite 9 (34.6) 2 (66.7) 3 (37.5) 1 (11.1) 0 (0) 1 (33.3) 16 (28.6) 6 (14.3) 5 (11.9) 1 (2.4) 0 (0) 12 (28.6) 
Abdominal 
distension 3 (11.5) 0 (0) 2 (25.0) 2 (22.2) 1 (14.3) 0 (0) 8 (14.3) 6 (14.3) 4 (9.5) 0 (0) 0 (0) 10 (23.8) 
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Blood alkaline 
phosphatase 
increased 
2 (7.7) 0 (0) 0 (0) 2 (22.2) 4 (57.1) 0 (0) 8 (14.3) 10 (23.8) 0 (0) 0 (0) 0 (0) 10 (23.8) 
Dyspnea 2 (7.7) 0 (0) 3 (37.5) 3 (33.3) 1 (14.3) 1 (33.3) 10 (17.9) 8 (19.0) 1 (2.4) 1 (2.4) 0 (0) 10 (23.8) 
Upper respiratory 
tract infection 1 (3.8) 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 2 (3.6) 6 (14.3) 4 (9.5) 0 (0) 0 (0) 10 (23.8) 
Cough 3 (11.5) 1 (33.3) 0 (0) 3 (33.3) 2 (28.6) 2 (66.7) 11 (19.6) 7 (16.7) 1 (2.4) 1 (2.4) 0 (0) 9 (21.4) 
Dizziness 2 (7.7) 1 (33.3) 2 (25.0) 2 (22.2) 2 (28.6) 0 (0) 9 (16.1) 7 (16.7) 1 (2.4) 1 (2.4) 0 (0) 9 (21.4) 
Table is sorted by decreasing incidence in Part 2A patients.  
a40 mg QD (n = 6), 80 mg QD (n =3), 160 mg QD (n = 4), 300 mg QD (n = 9), and 500 mg QD (n = 4).  
bAnemia and/or low/decreased hemoglobin. 
cThrombocytopenia and/or low or decreased platelets. 
dNeutropenia and/or low or decreased absolute neutrophil count. 
 638 
 639 
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Table 3. Antitumor activity in patients with advanced tumors who received rucaparib in Part 640 
1 and investigator-assessed response in patients with germline BRCA1/2-mutated ovarian 641 
cancer from Part 2A 642 
Part 1 (Phase I Dose Escalation)
Patients with Advanced Solid Tumors (n = 56) 
Dose Received 
Confirmed 
CR or PR 
(RECIST) 
Duration of 
Response 
(wk) 
Type of 
Cancer BRCA Mutation 
Platinum 
Status 
300 mg QD CR 111 Ovarian Germline BRCA1 Sensitive 
300 mg QD PR 15 Breast Germline BRCA1 NA 
360 mg BID CR 60 Breast Germline BRCA1 NA 
360 mg BID PR 28 Pancreatic Germline BRCA2 NA 
480 mg BID PR 116 Breast Germline BRCA2 NA 
480 mg BID PR 37 Ovarian Germline BRCA2 Resistant 
480 mg BID PR 21 Breast Tumor BRCA1 NA 
600 mg BID PR 13 Ovarian Tumor BRCA1 Resistant 
Part 2A (Phase II Expansion)
Patients with Germline BRCA1/2-Mutated Ovarian Cancer (n = 42) 
RECIST best confirmed response n (% [95% CI]) 
CR 4 (9.5) 
PR 21 (50.0) 
SD 12 (28.6) 
PD 2 (4.8) 
NE 3 (7.1) 
RECIST ORR 25 (59.5 [43.3–74.4]) 
RECIST/CA-125 ORR 35 (83.3 [68.6–93.0]) 
RECIST ORR by Part 2A patient subsets n/N (% [95% CI])  
BRCA gene mutation   
BRCA1 19/30 (63.3 [43.9–80.1]) 
BRCA2 6/12 (50.0 [21.1–78.9]) 
PFI    
6–12 mo 17/32 (53.1 [34.7–70.9]) 
>12 mo 8/10 (80.0 [44.4–97.5]) 
≥3 prior chemotherapy regimens 9/15 (60.0 [32.3–83.7]) 
Duration of response, median (95% CI), mo 7.8 (5.6–10.5) 
NA, not available; NE, not evaluable; PD, progressive disease. 
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Table 4. Single-dose and steady-state plasma pharmacokinetic parameters of rucaparib following once or twice daily continuous oral 644 
administration (Part 1, phase I dose escalation) 645 
Dosage N Day 
Arithmetic Mean 
Cmax (CV%), 
ng/mL 
Median 
Tmax (range), h 
Arithmetic 
Mean  
AUC0- τ (CV%), 
ng×h/mL 
Arithmetic 
Mean 
CLss/F (CV%), 
L/h AR (CV%) 
Arithmetic Mean
T1/2 (CV%), h 
40 mg QD 3 1 129 (28) 2.5 (1–4) 915
a NR NA 13.9 (57) 
15 138 (36) 4 (1–4.05) 1810 (44) 26.7 (59) 1.68a 25.7 (23)
80 mg QD 3 1 114 (41) 1.5 (1–2.5) 800 (27) NR NA 11.0
a
15 175 (37) 2.5 (2.5–2.57) 1740 (20) 47.5 (23) 2.33 (42) 19.5a
160 mg QD 4 1 261 (51) 4.0 (4–6.05) 3050 (51) NR NA 19.9 (21) 15 288 (29)b 3.75 (2.5–4)b 4110 (33)b 41.6 (29)b 1.84 (31)b 33.6 (12)b 
300 mg QD 3 1 629 (37) 2.5 (1–4.08) 5740 (38) NR NA 15.2 (72) 15 693 (76) 2.53 (2.5–8) 9610 (83) 46.7 (63) 1.60 (53) 29.8a 
500 mg QD 3 1 949 (52) 4 (4–4) 11,000 (61) NR NA 15.0 (32) 15 1390 (23) 4 (4–4.17) 19,900 (41) 27.8 (35) 1.94 (17) 20.8 (38) 
240 mg BID 3 1 219 (72) 6 (4.05–6) 2800
c NR NA 
NRh 
15 971 (49) 1.5 (1–4) 10,700a 27.3a 5.44c 
360 mg BID 8 1 666 (58) 3.23 (1.5–6) 4860 (58)
d NR NA 
15 1300 (43)d 3.3 (0–6.33)d 9430a 40.4a 4.08a 
480 mg BID 9 1 1150 (57) 2.5 (1.5–4) 8810 (63)
e NR NA 
15 3170 (69)e 1.51 (0–6)e 26,300 (73)d 26.2 (63)d 3.97 (38)f 
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Dosage N Day 
Arithmetic Mean 
Cmax (CV%), 
ng/mL 
Median 
Tmax (range), h 
Arithmetic 
Mean  
AUC0- τ (CV%), 
ng×h/mL 
Arithmetic 
Mean 
CLss/F (CV%), 
L/h AR (CV%) 
Arithmetic Mean
T1/2 (CV%), h 
600 mg BID 7 1 1030 (61) 4 (2.42–10) 7200 (66)
g NR NA 
15 2420 (45) 4 (2.53–10) 21,400 (61)g 58.6 (123)g 3.23 (66)g 
840 mg BID 3 1 1380 (69) 4 (2.5–8) 13,200
a NR NA 
15 3030 (NR)a 4.04 (4–4.07)a 29,000c 29c 1.47c 
an = 2; bn = 3; cn = 1; dn = 6; en = 8; fn = 5; gn = 4; hT1/2 is too long to allow for accurate estimate in BID dosing.  
AR, accumulation ratio based on AUC; AUC0-τ, area under the plasma concentration-time curve from 0 to the end of dosing interval (τ = 24 h for 
QD; τ = 12 h for BID; for BID dosing, concentration at 12 h was calculated by extrapolation from last observed concentration in the same dosing 
interval); NA, not available; NR, not reportable; CV, coefficient of variation.   
 646 
 647 
Kristeleit et al (phase I–II results for study CO-338-010) 
32 
 
FIGURE LEGENDS 648 
Figure 1.  649 
Waterfall plots for best overall change from baseline in target lesions in (A) patients with 650 
advanced solid tumors (Part 1, phase I dose escalation; n = 40) and (B) patients with 651 
germline BRCA1/2-mutated high grade ovarian cancer (Part 2A, phase II expansion; n = 40) 652 
who had both baseline and postbaseline measurements. (C) Duration of response for 653 
patients in Part 2A. In panel A, patients with a BRCA1 or BRCA2 mutation detected by local 654 
testing are indicated with triangles or circles; for mutations detected in tumor tissue only 655 
(open triangles and circles), germline status was not determined. 656 
 Figure 2.  657 
Baseline and on-treatment values for (A) alanine aminotransferase, (B) aspartate 658 
aminotransferase, and (C) bilirubin for patients in Part 2A (n = 42). Dashed grey lines 659 
indicate the upper and lower limits of the normal range. SEM, standard error of the mean. 660 
 661 
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